Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Cons

Date

26 Mar 2025

Session

Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Topics

Radiological Imaging; Staging Procedures; Response Evaluation (RECIST Criteria); Immunotherapy; Surgical Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Nan Wu

Authors

N. Wu

Author affiliations

Peking University Cancer Hospital and Institute, Beijing/CN

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

26 Mar 2025

Introduction and first vote

Presenter: Paul van Schil

Session: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Resources:

Slides

Webcast

26 Mar 2025

Pros

Presenter: Leah Backhus

Session: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Resources:

Slides

Webcast

26 Mar 2025

Second vote and conclusions/discussion

Presenter: Paul van Schil

Session: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Resources:

Slides

Webcast